Network Meta-Analysis Sheds Light on Efficacy of Lenvatinib Plus Pembrolizumab Vs SOC in Advanced RCC

Lenvatinib/pembrolizumab shows a trend of improved PFS and overall response rate vs standard immunotherapies in advanced renal cell carcinoma.

Related Keywords

Lenvatinib Lenvima ,International Metastatic ,Database Consortium ,Lenvatinib Pembrolizumab ,Advanced Renal Cell Carcinoma ,